British Ivermectin Recommendation Development Panel – Response to EMA Statement on Ivermectin for Covid-19

On 22 March, the European Medicines Agency (EMA) issued a statement that, after reviewing the evidence, they recommend against the use of ivermectin for the prevention and treatment of covid-19, outside of ‘well-designed’ clinical trials. The EMA claims evidence from laboratory studies, clinical trials, observational studies, and meta-analysis, but provides no sources, specifics or citations. We fill these omissions below.

The British Ivermectin Recommendation Development (BIRD) panel was set up in January 2021 by Dr Tess Lawrie of the Evidence-Based Medicine Consultancy Ltd (E-BMC), an independent medical research company based in Bath, UK.  A systematic review and meta-analysis of ivermectin for covid-19 was recently conducted by Dr Lawrie, the director, with a team of expert systematic reviewers. A preliminary report was released in the public domain on 3 January [1]. A comprehensive paper including 21 RCTs has been submitted to a peer-reviewed journal, and meanwhile is available on two pre-print servers [2 ,3].  Moreover, on 20 February 2021, a panel of 65 clinicians, researchers and patient representatives from 16 countries attended the BIRD panel meeting, conven...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee